Fragmin for Venous thromboembolism treatment and prophylaxis
Quick answer: Fragmin is used for Venous thromboembolism treatment and prophylaxis as part of a low molecular weight heparin (lmwh) treatment regimen. Dalteparin potentiates antithrombin III to inhibit factor Xa (and to a lesser extent thrombin) The specific dosing for Venous thromboembolism treatment and prophylaxis is determined by your prescriber based on individual factors.
Why is Fragmin used for Venous thromboembolism treatment and prophylaxis?
Fragmin belongs to the Low molecular weight heparin (LMWH) class. Dalteparin potentiates antithrombin III to inhibit factor Xa (and to a lesser extent thrombin) This action makes it useful for treating or managing Venous thromboembolism treatment and prophylaxis in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Fragmin is the right choice for a specific patient depends on the type and severity of Venous thromboembolism treatment and prophylaxis, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Venous thromboembolism treatment and prophylaxis
Common adult dosing range: Prophylaxis 2500-5000 IU SC daily; treatment 200 IU/kg SC daily or 100 IU/kg SC twice daily. The actual dose for Venous thromboembolism treatment and prophylaxis depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Fragmin medicine page.
What to expect
Fragmin treatment for Venous thromboembolism treatment and prophylaxis typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Venous thromboembolism treatment and prophylaxis
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Fragmin is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all Low molecular weight heparin (LMWH) for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Fragmin
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Fragmin full prescribing information · All Low molecular weight heparin (LMWH) alternatives
Frequently asked questions
How effective is Fragmin for Venous thromboembolism treatment and prophylaxis?
Effectiveness varies by individual response, dose, and severity. Fragmin is one of several treatment options for Venous thromboembolism treatment and prophylaxis, supported by clinical evidence within the low molecular weight heparin (lmwh) class. Discuss expected response with your prescriber.
How long do I need to take Fragmin for Venous thromboembolism treatment and prophylaxis?
Treatment duration depends on the nature of Venous thromboembolism treatment and prophylaxis — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Fragmin when used for Venous thromboembolism treatment and prophylaxis?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Fragmin for Venous thromboembolism treatment and prophylaxis?
Yes. Multiple medicines and non-drug options exist for Venous thromboembolism treatment and prophylaxis. Alternatives within the low molecular weight heparin (lmwh) class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.